Your browser doesn't support javascript.
loading
Comparisons of different new-generation transcatheter aortic valve implantation devices for patients with severe aortic stenosis: a systematic review and network meta-analysis.
Yang, Yi-Xing; Liu, Xin-Ming; Fu, Yuan; Li, Chuang; Wang, Hong-Jiang; Xu, Li; Xia, Kun; Zhang, Zhi-Yong; Zhong, Jiu-Chang; Chen, Mu-Lei; Su, Pi-Xiong; Wang, Le-Feng.
Afiliação
  • Yang YX; Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang District, Beijing, China.
Int J Surg ; 109(8): 2414-2426, 2023 Aug 01.
Article em En | MEDLINE | ID: mdl-37161443
ABSTRACT

BACKGROUND:

Whether there are differences among the new-generation transcatheter aortic valve implantation (TAVI) devices for patients with aortic stenosis remains unclear. The aim of the study was to compare the efficiency and safety of different new-generation TAVI devices for patients with aortic stenosis. MATERIALS AND

METHODS:

A comprehensive search of PubMed, Embase and Web of Science from their inception to 1 February 2022. Randomized clinical trials and observational studies that compared two or more different TAVI devices were enroled. Pairwise meta-analysis and frequentist network meta-analysis were conducted to pool the outcome estimates of interest.

RESULTS:

A total of 79 studies were finally included. According to the surface under the cumulative ranking, the top two ranked valves for lower rates of events were as follows direct flow medical (DFM) (4.6%) and Lotus (48.8%) for lower rate of device success; Sapien 3 (16.8%) and DFM (19.7%) for lower mortality; DFM (8.6%) and Sapien 3 (25.5%) for lower rates of stroke; Evolut (27.6%) and DFM (35.8%) for lower rates of major and life-threatening bleeding; Portico (22.6%) and Sapien 3 (41.9%) for lower rates of acute kidney injury; Acurate (8.6%) and DFM (13.2%) for lower rates of permanent pacemaker implantation; Lotus (0.3%) and Sapien 3 (22.7%) for lower rates of paravalvular leak; Evolut (1.4%) and Portico (29.1%) for lower rates of mean aortic valve gradients.

CONCLUSIONS:

The findings of the present study suggested that the device success rates were comparable among these new-generation valves except for DFM. After excluding DFM, Sapien 3 might be the best effective for decreased mortality and stroke; Lotus might be the best effective for decreased paravalvular leak; Evolut might be the best effective for decreased major and life-threatening bleeding and mean aortic valve gradients; Acurate and Portico might be the best effective for decreased permanent pacemaker implantation and acute kidney injury, respectively.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Acidente Vascular Cerebral / Injúria Renal Aguda / Substituição da Valva Aórtica Transcateter Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Acidente Vascular Cerebral / Injúria Renal Aguda / Substituição da Valva Aórtica Transcateter Idioma: En Ano de publicação: 2023 Tipo de documento: Article